Medplus Health Services Limited
NSE: MEDPLUSPharmacy Retail
Share price
₹631.90
-2.38% close of 8 Oct 2026
Business score
How strong the business is, in one number. The parts behind it are in Pro.
66
out of 100 · worked out 8 Oct 2026
Your ratios
The numbers you want to see first. Tap Edit to change them.
Market cap
₹7,583 Cr
P/E ratio
36.0
P/B ratio
3.8
ROCE
12.6%
ROE
11.6%
Dividend yield
0.0%
Price & valuation chart
How the share price and its valuation have moved. Hover over the chart to see any day. Prices as of the last close.
Answers
Simple answers to the questions investors ask most, from the company's own numbers.
How fast it has been growing
Sales grew 16.8% over the past year, and 15.7% a year over its longer record. Meanwhile what it keeps of every 100 rupees of sales improved from 6.0% to 8.4% over the last four years.
Whether it grew faster than its sector
It grew 15.7% a year against a sector median of 13.9% — 1.7 percentage points faster.
Room to re-rate, or risk of de-rating
At 36.0× earnings it costs 1.5× the market, which pays 23.9× across 2199 companies we can price. Its own industry sits at 83.9×, across 3 companies. It is against its own five-year median of 103.3×, the 0th percentile of its own range.
Whether growth justifies the valuation
Priced at 0.5 times its growth rate, on earnings growth of 66%.
| Profit growth | Price per ₹1 profit | Per 1% growth | |
|---|---|---|---|
| Medplus Health Services Limited — this one | 66%/yr | 36.0× | ₹0.55 |
| ETERNAL LIMITED | 28%/yr | — | — |
| Avenue Supermarts Limited | 8%/yr | 76.4× | ₹9.6 |
| Trent Limited | 71%/yr | 83.9× | ₹1.2 |
| Lenskart Solutions Limited | 110%/yr | 172.4× | — |
| Meesho Limited | 6%/yr | — | — |
Compared with companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.
How it compares with its peers
Against companies across the whole Consumer Services sector, it ranks 55 of 130 on returns, 57 of 120 on growth, 87 of 129 on margin. That grouping comes from the exchange's filing category, so some of them may not be real rivals.
What makes it hard to beat — and is that still true?
A narrow advantage: it earns 12.6% on capital, ahead of 58% of companies across its whole sector. That grouping comes from the exchange's filing category, so some of them may not be real rivals.
Whether its growth pays for itself
Yes — Over the last five years it made ₹1440 crore of cash from the business, spent ₹546 crore on plant and equipment, and returned ₹412 crore to lenders and shareholders. And the profit is real: of every 100 rupees it reported over 12 years, about 217 arrived as cash — well above the profit; depreciation and interest are the reason, not a windfall. Its cash comes back faster than it used to: it went from being waiting 100 days for its cash to waiting 49 days for its cash.
Profit reality check
Is the profit real cash? Simple checks on the accounts. Facts only, not advice.
7 of 9 checks clear · 78%
Latest result
What the last results showed. Whether management kept its word is in Pro.
Results are expected soon.
Checklist before you investPRO
Points for and against, in one list.
Key numbers & peers
The main numbers grouped by topic, and how the company compares with similar ones.
Price
- Market cap
- ₹7,583 Cr
- Prev close
- ₹631.90
- 52w High
- ₹1,022
- 52w Low
- ₹627
- Enterprise value
- ₹8,545 Cr
- Beta
- 0.7
- Price CAGR 1y
- -15.0%
- Price CAGR 3y
- -6.0%
- Price CAGR 5y
- —
- Price CAGR 10y
- —
Ratios
- Return on assets
- 5.6%
- PEG ratio
- 0.5
- P/E ratio
- 36.0
- P/B ratio
- 3.8
- EV / EBITDA
- 14.0
- Industry P/E
- 30.9
- ROCE
- 12.6%
- ROCE 5y average
- 9.0%
- ROE
- 11.6%
- Debt / Equity
- 0.7
- Interest coverage
- 3.3
- Dividend yield
- 0.0%
- ROE 3y average
- 8.0%
- ROE last year
- 12.0%
Annual P&L
- Annual revenue
- ₹6,892 Cr
- Annual profit
- ₹220 Cr
- Operating margin
- 9.0%
- Net profit margin
- 3.2%
- EBITDA margin
- 8.8%
- Sales growth 3y
- 14.8%
- Sales growth 5y
- 17.6%
- Profit growth 3y
- 66.0%
- Profit growth 5y
- 28.0%
- EPS
- ₹18.3
- Sales growth TTM
- 17.0%
- Profit growth TTM
- 18.0%
- Dividend payout
- 0.0%
Quarter P&L
- Sales latest quarter
- ₹1,880 Cr
- Profit latest quarter
- ₹33 Cr
- YoY quarterly sales growth
- 21.8%
- YoY quarterly profit growth
- -21.4%
- OPM latest quarter
- 7.1%
Balance Sheet
- Book Value
- ₹165
- Face Value
- ₹2.0
- Total debt
- ₹1,424 Cr
- Total cash
- ₹462 Cr
- Borrowings
- ₹1,424 Cr
- Reserves / Equity
- 81.3
Cash Flow
- Operating cash flow
- ₹496 Cr
- Free cash flow
- ₹373 Cr
- FCF yield
- 3.3%
- Net cash flow
- ₹112 Cr
Shareholding
- Promoter holding
- 40.2%
- FII holding
- 14.4%
- DII holding
- 29.9%
- Public holding
- 15.4%
Peer comparison
| Company | Price ₹ | P/E | Mkt cap ₹ Cr | Div yield % | Profit qtr ₹ Cr | Profit var % | Sales qtr ₹ Cr | Sales var % | ROCE % |
|---|---|---|---|---|---|---|---|---|---|
| Medplus Health | 641.40 | 36.6 | 7,706 | 0.00 | 33.2 | -21.7 | 1,879.6 | 21.8 | 12.6 |
| Entero Healthcar | 1,704.70 | 57.5 | 7,419 | 0.00 | 52.1 | 37.3 | 1,940.5 | 38.2 | 10.5 |
| Median | 1,173.05 | 47.0 | 7,562 | 0.00 | 42.6 | 7.8 | 1,910.1 | 30.0 | 11.5 |
Competes with: Entero Healthcare Solutions Limited, Sastasundar Ventures Limited
Quarterly results
Sales and profit for each of the last 13 quarters. Newest on the right. ₹ crore.
| Line item | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,284 | 1,409 | 1,441 | 1,491 | 1,489 | 1,576 | 1,561 | 1,510 | 1,543 | 1,679 | 1,806 | 1,864 | 1,880 |
| Expenses | 1,213 | 1,324 | 1,350 | 1,385 | 1,395 | 1,452 | 1,429 | 1,373 | 1,412 | 1,530 | 1,648 | 1,695 | 1,746 |
| Material Cost | 19 | 23 | 21 | 26 | 21 | ||||||||
| Change in Inventories | 68 | -4.05 | -48 | -50 | -60 | ||||||||
| Purchases of Stock-in-Trade | 1,053 | 1,221 | 1,362 | 1,395 | 1,459 | ||||||||
| Employee Cost | 200 | 213 | 233 | 238 | 242 | ||||||||
| Other Expenses | 72 | 77 | 81 | 86 | 85 | ||||||||
| Operating Profit | 71 | 85 | 92 | 106 | 94 | 124 | 133 | 136 | 131 | 149 | 159 | 169 | 133 |
| OPM % | 5.56 | 6.04 | 6.37 | 7.10 | 6.30 | 7.90 | 8.49 | 9.03 | 8.47 | 8.86 | 8.78 | 9.07 | 7.09 |
| Other Income | 9 | 10 | 10 | 10 | 9 | 12 | 13 | 16 | 15 | 17 | 18 | 21 | 20 |
| Exceptional items (within Other Income) | 0 | 0 | 0 | 0 | 0 | ||||||||
| Interest | 23 | 24 | 24 | 25 | 25 | 25 | 26 | 27 | 27 | 29 | 31 | 33 | 33 |
| Depreciation | 52 | 55 | 57 | 59 | 60 | 63 | 62 | 64 | 66 | 69 | 73 | 76 | 78 |
| Profit before tax | 5 | 16 | 20 | 32 | 18 | 48 | 57 | 61 | 53 | 69 | 73 | 80 | 42 |
| Tax % | 26 | 12 | 31 | -5 | 19 | 19 | 19 | 16 | 20 | 19 | 21 | 20 | 21 |
| Net Profit | 4 | 15 | 14 | 34 | 14 | 39 | 46 | 51 | 42 | 56 | 58 | 64 | 33 |
| EPS in Rs | 0.32 | 1.22 | 1.15 | 2.79 | 1.20 | 3.24 | 3.83 | 4.29 | 3.54 | 4.63 | 4.82 | 5.33 | 2.76 |
| Diluted EPS in Rs | 3.53 | 4.62 | 4.81 | 5.33 | 2.76 |
Profit & loss
Yearly sales, costs and profit for 12 years, plus the last 12 months (TTM). ₹ crore.
| Line item | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,368 | 1,733 | 2,011 | 2,131 | 2,273 | 2,871 | 3,069 | 3,779 | 4,558 | 5,625 | 6,136 | 6,892 | 7,229 |
| Expenses | 1,336 | 1,696 | 1,940 | 2,073 | 2,153 | 2,737 | 2,852 | 3,507 | 4,292 | 5,270 | 5,648 | 6,284 | 6,620 |
| Material Cost | 89 | ||||||||||||
| Change in Inventories | -35 | ||||||||||||
| Purchases of Stock-in-Trade | 5,030 | ||||||||||||
| Employee Cost | 885 | ||||||||||||
| Other Expenses | 316 | ||||||||||||
| Operating Profit | 32 | 37 | 71 | 58 | 120 | 134 | 217 | 273 | 266 | 355 | 488 | 608 | 610 |
| OPM % | 2.40 | 2.10 | 3.50 | 2.70 | 5 | 4.70 | 7 | 7 | 6 | 6 | 8 | 9 | 8 |
| Other Income | 4 | 8 | 7 | 8 | 11 | 17 | 21 | 31 | 46 | 40 | 48 | 71 | 76 |
| Exceptional items (within Other Income) | 0 | ||||||||||||
| Interest | 14 | 17 | 19 | 28 | 50 | 47 | 55 | 66 | 83 | 96 | 103 | 120 | 126 |
| Depreciation | 9 | 10 | 11 | 12 | 59 | 75 | 88 | 119 | 182 | 224 | 250 | 283 | 295 |
| Profit before tax | 14 | 19 | 48 | 26 | 23 | 29 | 95 | 118 | 47 | 73 | 183 | 275 | 264 |
| Tax % | 46 | 52 | 40 | -65 | 48 | 94 | 34 | 20 | -6 | 11 | 18 | 20 | |
| Net Profit | 7 | 9 | 29 | 42 | 12 | 2 | 63 | 95 | 50 | 66 | 150 | 220 | 210 |
| EPS in Rs | 419 | 509 | 1,621 | 2,080 | 585 | 107 | 1,393 | 8.03 | 4.17 | 5.48 | 13 | 18 | 18 |
| Diluted EPS in Rs | 18 | ||||||||||||
| Dividend Payout % | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
Compounded growth
Average yearly growth over different spans, as stored. A span can cross a demerger or an acquisition.
Compounded sales growth
- 10 years
- 15%
- 5 years
- 18%
- 3 years
- 15%
- TTM
- 17%
Compounded profit growth
- 10 years
- 37%
- 5 years
- 28%
- 3 years
- 66%
- TTM
- 18%
Stock price CAGR
- 10 years
- —
- 5 years
- —
- 3 years
- -6%
- 1 year
- -15%
Return on equity
- 10 years
- 8%
- 5 years
- 7%
- 3 years
- 8%
- Last year
- 12%
Balance sheet
What the company owns and what it owes, at the end of each year. ₹ crore.
| Line item | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.17 | 0.17 | 0.17 | 0.19 | 0.19 | 0.19 | 0.45 | 24 | 24 | 24 | 24 | 24 |
| Reserves | 141 | 137 | 148 | 303 | 291 | 528 | 730 | 1,394 | 1,467 | 1,554 | 1,717 | 1,951 |
| Borrowings | 170 | 223 | 204 | 162 | 429 | 477 | 590 | 815 | 900 | 1,010 | 1,120 | 1,424 |
| Other Liabilities | 126 | 149 | 183 | 179 | 239 | 344 | 245 | 361 | 406 | 417 | 500 | 533 |
| Minority Interest | -0.71 | |||||||||||
| Total Liabilities | 438 | 509 | 535 | 644 | 959 | 1,349 | 1,566 | 2,594 | 2,797 | 3,005 | 3,360 | 3,933 |
| Fixed Assets | 67 | 77 | 81 | 83 | 377 | 419 | 517 | 799 | 1,138 | 1,242 | 1,296 | 1,595 |
| CWIP | 3 | 3 | 2 | 1 | 1 | 5 | 6 | 20 | 25 | 11 | 16 | 32 |
| Investments | 0 | 0 | 0 | -0 | -0 | 0 | 0 | 0 | 0 | -0 | -0 | -0 |
| Other Assets | 368 | 429 | 453 | 560 | 580 | 924 | 1,043 | 1,775 | 1,633 | 1,752 | 2,047 | 2,306 |
| Total Assets | 438 | 509 | 535 | 644 | 959 | 1,349 | 1,566 | 2,594 | 2,797 | 3,005 | 3,360 | 3,933 |
Cash flows
Real money coming in and going out each year — from the business, from investments and from loans. ₹ crore.
| Line item | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | -19 | -17 | 34 | 32 | 147 | -7 | 3 | 170 | 90 | 144 | 540 | 496 |
| Cash from Investing Activity | -16 | -32 | -15 | -18 | -19 | -28 | -35 | -703 | 429 | -83 | -318 | -128 |
| Cash from Financing Activity | 67 | 35 | -29 | -1 | -83 | 90 | -6 | 440 | -170 | -198 | -228 | -256 |
| Net Cash Flow | 32 | -15 | -10 | 14 | 45 | 56 | -37 | -93 | 350 | -137 | -5 | 112 |
| Free Cash Flow | -35 | -35 | 19 | 32 | 125 | -37 | -51 | 56 | -78 | 61 | 482 | 373 |
Ratios
How fast customers pay, how long stock sits, and how well capital earns — year by year.
| Line item | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 1 | 1 | 0 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Inventory Days | 84 | 82 | 76 | 76 | 78 | 101 | 113 | 112 | 117 | 111 | 106 | 99 |
| Days Payable | 34 | 29 | 25 | 27 | 31 | 37 | 22 | 30 | 27 | 21 | 24 | 22 |
| Cash Conversion Cycle | 51 | 53 | 51 | 51 | 48 | 65 | 91 | 82 | 91 | 92 | 83 | 79 |
| Working Capital Days | 16 | 12 | 14 | 13 | 8 | 25 | 46 | 100 | 58 | 58 | 54 | 49 |
| ROCE % | 11 | 19 | 13 | 12 | 9 | 13 | 10 | 5 | 7 | 10 | 13 |
Price trend
The price as a Renko brick chart: small moves drop out so the bigger path stands out.
Every brick is the same size, about one typical day's move. A new brick needs a full brick's move; turning the other way needs two. Bricks show where the price went, not where it will go.
Open interestPRO
Where option traders are positioned on this stock.
Industry numbers
The numbers that matter most in this industry, from the company's own filings.
1 when an audit qualification is filed as repetitive
0.00flag
2026-03-31
the company's own unlisted debt securities in default at period end
0.00cr
2026-06-30
the company's own loans / revolving facilities in default at period end (standalone filing)
0.00cr
2026-06-30
net debt from the filed balance sheet at the newest year end: Borrowings − Cash Equivalents − Investments (Current); negative = net cash
962inr_cr
2026-03-31
guarantees / comfort given for promoter, promoter group, directors and KMP
0.00cr
2026-03-31
loans outstanding to promoter, promoter group, directors and KMP (governance filing)
0.00cr
2026-03-31
security given for the borrowing of promoter, promoter group, directors and KMP
0.00cr
2026-03-31
FY revenue / permanent employees + workers, same basis (calc)
3,10,831inr
2026-03-31
News
News and filings about Medplus Health Services Limited. Open one to see why it matters.
No recent news for this company.
Supply chain
Who it buys from, sells to and competes with — as recorded in our map of company links.
Competes with
- Entero Healthcare Solutions Limited
- Sastasundar Ventures Limited
Uses as raw material
- Packing materials
- Raw materials for private-label manufacturing
- Stock-in-trade: pharmaceutical products and general/FMCG items
Buys from
- Akums Drugs and Pharmaceuticals Limited · CDMO / private-label manufacturing of formulations
About
What the company is, from our own records: where it sits, where it makes things, and what it is made of.
- Sector
- Consumer Services
- Industry
- Pharmacy Retail
- Classification
- Consumer Services › Pharmacy Retail
- ISIN
- INE804L01022
Business segments
- Retail · 98%
- Diagnostic services · 2%
- Others · 0%
Plants
- MedPlus Kallakal factory
- MedPlus Moosapet factory
- MedPlus Pashamylaram factory - Plot 110
- MedPlus Pashamylaram factory - Plot 221/B
- MedPlus Shamirpet factory
News impact
Big market events that reach Medplus Health Services Limited, and how the effect spreads.
1 Oct, 12:36 IST · Market event · medium impact
Food Safety Crackdown: Licences Of Swiggy Instamart, Flipkart, Zepto Dark Stores Suspended In Telangana
Telangana shut Swiggy Instamart, Flipkart and Zepto dark stores over rotten food and pests, hurting Swiggy and clouding food stocks while nearby grocers pick up the slack.
Who it hits first
- Telangana food-safety officers suspended the licences of Swiggy Instamart, Flipkart and Zepto dark stores after finding expired food, pest-infested articles and rotting vegetables.
- A dark store is a small warehouse that packs 10-minute grocery deliveries, so a suspended licence means zero sales from that store until it passes re-inspection.
- Swiggy is the only listed name directly hit, since Flipkart and Zepto are unlisted and carry no stock signal.
Who may gain
- Avenue Supermarts, the DMART grocery-store chain, catches weekly baskets diverted from shut dark stores in Telangana neighbourhoods.
- Vishal Mega Mart, the budget grocery and clothing retailer, picks up price-sensitive shoppers avoiding suspended quick-commerce apps.
- No supplier or rider gains — snack makers lose a sales channel and delivery riders lose shifts while stores stay shut.
- Flipkart and Zepto are unlisted, so their share of the pain carries no stock signal here.
Along the supply chain
Downstream
Delivery riders attached to shut dark stores lose shifts and payouts, while shoppers fall back on kirana shops, DMART and Vishal Mega Mart for the weekly basket.
Upstream
Snack and staple suppliers that fed the shut stores — Bikaji Foods (packaged snacks) and KRBL (rice) are named Swiggy suppliers in the graph — lose a Telangana sales channel, though neither has a fundamentals row here so no signal can be written for them.
Where demand moves
Business
Grocery orders that flowed through Instamart, Flipkart and Zepto apps in Telangana reroute to DMART stores, Vishal Mega Mart outlets and kirana shops until licences return.
Capital
Investors mark down quick-commerce exposure on regulatory risk while nudging grocery-retail names up on the diverted demand, keeping food-delivery multiples under watch.
How it spreads across sectors
Consumer Services
Quick-commerce and food-delivery names face licence and headline risk, QSR chains wear mild spillover scrutiny, while store-based grocers absorb the diverted weekly shop.
A pattern seen before
Cascade chain
Pattern name
Crude Oil Cascade
Patterns
- Crude Oil Cascade
Sectors queried
- Cement
- Chemicals
- FMCG
- Power
When it plays out
Immediate
In 1-7 days Swiggy slips on the headline while grocers firm; watch for the re-inspection schedule and any extension to other cities.
Medium term
In 1-6 months the episode fades if licences return fast, but a wider hygiene drive would raise compliance costs across quick commerce.
Short term
In 1-4 weeks QSR and delivery names trade on whether copycat raids appear in other states or the matter stays a Telangana-only cleanup.
Dividends, splits & big trades
Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.
Splits, bonuses & buybacks
- daily-prices repair: 7 rows from NSE's archive (replace 2, delete 0, insert 5), 2023-11-12..2026-02-01 (docs/flat_day_repair.md)1× · 12 Nov 2023
Insider trades
| Disclosed | Who | Type | Shares | Value ₹ Cr |
|---|---|---|---|---|
| 1 Sep 2026 | Alka Ajit Rangnekar · Directors Immediate Relative | BUY | 3,725 | 0.24 |
Documents
Annual reports, results presentations and earnings calls, straight from the source.
- Annual report · 2025-2623 Jul 2026
- Earnings call · Q1FY2722 Jul 2026
- Results presentation30 Jun 2026
Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.